title: [Long-term results of the anti-emetic effectiveness of the 5-HT3 antagonist ondansetron].
abstract: 40 patients with metastatic breast cancer, under treatment with epirubicin (greater than 50 mg/m2) and cyclophosphamide (greater than 500 mg/m2), had an antiemetic therapy with Ondansetron 3 x 8 mg day, for a maximum of 10 cycles. A total of 128 treatment cycles were analysed. There was no reduction in antiemetic efficacy, regarding vomits/day and grade of nausea. 77% (31/40) had a steady or better control of vomiting during the whole treatment period. Only 23% experienced a reduction in the antiemetic efficacy in repeated therapy. 60-100% of the patients also had control of nausea (mild or none). Generally, there were no signs for a reduction of the antiemetic efficacy of Ondansetron in repeated therapy. There were neither clinically relevant side effects nor changes in laboratory values related to Ondansetron.
authors: Medizinische Universitätsklinik Göttingen.
authors: N W
authors: NW
authors: Marschner
authors: M
authors: M
authors: Adler
authors: F
authors: F
authors: Jaenicke
authors: U
authors: U
authors: Albrecht
authors: G A
authors: GA
authors: Nagel
mesh_terms: D000932:Antiemetics / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004311:Double-Blind Method; D015251:Epirubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use*; D008787:Metoclopramide / Q000627:therapeutic use; D009362:Neoplasm Metastasis; D017294:Ondansetron; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy*
chemical_list: D000932:Antiemetics; D007093:Imidazoles; D012702:Serotonin Antagonists; D015251:Epirubicin; D017294:Ondansetron; D003520:Cyclophosphamide; D008787:Metoclopramide
vernacular_title: Langzeitergebnisse der antiemetischen Effektivität des 5-HT3-Antagonisten Ondansetron.